Home  |  Contact

Cellosaurus MDA-MB-231-MEK-R (CVCL_V403)

[Text version]

Cell line name MDA-MB-231-MEK-R
Accession CVCL_V403
Resource Identification Initiative To cite this cell line use: MDA-MB-231-MEK-R (RRID:CVCL_V403)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901).
Sequence variations Heterozygous for BRAF p.Gly464Val (c.1391G>T) (ClinVar=VCV000040364) (from parent cell line).
Homozygous for CDKN2A deletion (from parent cell line).
Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (from parent cell line).
TERT c.228C>T (-124C>T); in promoter (from parent cell line).
Homozygous for TP53 p.Arg280Lys (c.839G>A) (ClinVar=VCV000376657) (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0062 (MDA-MB-231)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line

PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010
Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P., Haverty P.M., Soriano R., Forrest W.F., Heldens S., Chen H., Toy K., Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M., Moffat J., Belvin M., Lackner M.R.
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Mol. Cancer Ther. 11:1143-1154(2012)

Other Wikidata; Q54904605
Polymorphism and mutation databases Cosmic; 1927243
Entry history
Entry creation16-Apr-2014
Last entry update02-Jul-2020
Version number12